Phase 1 Clinical Trial of Human Hookworm Vaccine Successfully Completed

WASHINGTON, D.C. — September 3, 2014 — The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) successfully completed a Phase 1 clinical trial in Brazil of Na-GST-1/Alhydrogel®, a vaccine candidate for human hookworm, one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poor. The Sabin PDP is based at Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine in Houston, Texas.

Bollywood Celebrity Abhishek Bachchan Named Ambassador for END7 Campaign

MUMBAI, INDIA – February 10, 2014 – The Global Network for Neglected Tropical Diseases (Global Network) today named Abhishek Bachchan, Bollywood superstar and international humanitarian, as its first official END7 campaign ambassador in India to help raise awareness of neglected tropical diseases (NTDs). Mr. Bachchan joins the END7 campaign at a crucial time, with India at the tipping point of achieving control and elimination of five NTDs affecting 500 million people by 2020.

New Global Consortium to Advance First-Ever Clinical Testing of the Human Hookworm Vaccine in Sub-Saharan Africa

AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people. Under this grant, the HOOKVAC consortium, which includes partners from the European Union, United States and Africa, will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.

Pages